An overview of recent studies on the analysis of pharmaceutical polymorphs

Journal of Pharmaceutical and Biomedical Analysis

Volumn 55, Issue 4, 2011, Pages 618-644

  Chieng, Norman ^a   Rades, Thomas ^b   Aaltonen, Jaakko ^c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Amorphous; Cocrystal; Crystallization; Polymorphism; Solid state analytical techniques; Solvatomorphism

Indexed keywords

ANALYTIC METHOD; BIOTRANSFORMATION; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; FOURIER TRANSFORMATION; INFRARED SPECTROSCOPY; MICROCALORIMETRY; NEAR INFRARED SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RAMAN SPECTROMETRY; REFLECTOMETRY; REVIEW; SCANNING ELECTRON MICROSCOPY; SOLID STATE; TERAHERTZ SPECTROSCOPY; THERMOGRAVIMETRY; X RAY DIFFRACTION;

CALORIMETRY; CHEMISTRY TECHNIQUES, ANALYTICAL; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; MICROSCOPY; SOLVENTS; SPECTROPHOTOMETRY; SPECTRUM ANALYSIS, RAMAN; X-RAY DIFFRACTION;

EID: 79955485358     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.12.020     Document Type: Review

References (266)

1. Brittain H.G. Polymorphism in Pharmaceutical Solids 2009, Informa Healthcare USA, Inc., New York. 2nd ed.
2. Hilfiker R. Polymorphism in the Pharmaceutical Industry 2006, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
3. Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv. Drug Deliv. Rev. 2001, 48:27-42.
4. Rodriguez-Spong B., Price C.P., Jayasankar A., Matzger A.J., Rodriguez-Hornedo N. General principles of pharmaceutical solid polymorphism: a supramolecular perspective. Adv. Drug Deliv. Rev. 2004, 56:241-274.
5. Pudipeddi M., Serajuddin A.T. Trends in solubility of polymorphs. J. Pharm. Sci. 2005, 94:929-939.
6. Hancock B.C., Parks M. What is the true solubility advantage of amorphous pharmaceuticals?. Pharm. Res. 2000, 17:397-404.
7. Miroshnyk I., Mirza S., Sandler N. Pharmaceutical co-crystals - an opportunity for drug product enhancement. Exp. Opin. Drug Deliv. 2009, 6:333-341.
8. Stahly G. Diversity in single- and multiple-component crystals. The search for and prevalence of polymorphs and cocrystals. Cryst. Growth Des. 2007, 7:1007-1026.
9. Heinz A., Strachan C.J., Gordon K.C., Rades T. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy. J. Pharm. Pharmacol. 2009, 61:971-988.
10. Knapman K. Polymorphic predictions: understanding the nature of crystalline compounds can be critical in drug development and manufacture. Mod. Drug Discov. 2000, 3. 53-54, 57.
11. Byrn S., Pfeiffer R., Ganey M., Hoiberg C., Poochikian G. Pharmaceutical solids: a strategic approach to regulatory consideration. Pharm. Res. 1995, 12:945-954.
12. Buckton G.D.P. Assessment of disorder in crystalline powders - a review of analytical techniques and their application. Int. J. Pharm. 1999, 179:141-158.
13. Brittain H.G. Physical Characterization of Pharmaceutical Solids 1995, Marcel Dekker, Inc., New York.
14. Dong Z., Chatterji A., Sandhu H., Choi D.S., Chokshi H., Shah N. Evaluation of solid state properties of solid dispersions prepared by hot-melt extrusion and solvent co-precipitation. Int. J. Pharm. 2008, 355:141-149.
15. Sheikhzadeh M., Rohani S., Jutan A., Manifar T. Quantitative and molecular analysis of buspirone hydrochloride polymorphs. J. Pharm. Sci. 2007, 96:569-583.
16. Sheikhzadeh M., Rohani S., Jutan A., Manifar T., Murthy K., Horne S. Solid-state characterization of buspirone hydrochloride polymorphs. Pharm. Res. 2006, 23:1043-1050.
17. Vogt F.G., Brum J., Katrincic L.M., Flach A., Socha J.M., Goodman R.M., Haltiwanger R.C. Physical, crystallographic, and spectroscopic characterization of a crystalline pharmaceutical hydrate: understanding the role of water. Cryst. Growth Des. 2006, 6:2333-2354.
18. Gandhi R.B., Bogardus J.B., Bugay D.E., Perrone R.K., Kaplan M.A. Pharmaceutical relationships of three solid state forms of stavudine. Int. J. Pharm. 2000, 201:221-237.
19. Burnett D., Thielmann F., Sokoloski T. Investigating carbamazepine-acetone solvate formation via dynamic gravimetric vapor sorption. J. Therm. Anal. Calorim. 2007, 89:693-698.
20. Hu Y., Wikström H., Byrn S.R., Taylor L.S. Analysis of the effect of particle size on polymorphic quantitation by Raman spectroscopy. Appl. Spectrosc. 2006, 60:977-984.
21. Amado A.M., Nolasco M.M., Ribeiro-Claro P.J.A. Probing pseudopolymorphic transitions in pharmaceutical solids using Raman spectroscopy: hydration and dehydration of theophylline. J. Pharm. Sci. 2007, 96:1366-1379.
22. Mollica G., Geppi M., Pignatello R., Veracini C. Molecular properties of flurbiprofen and its solid dispersions with eudragit RL100 studied by high- and low-resolution solid-state nuclear magnetic resonance. Pharm. Res. 2006, 23:2129-2140.
23. Bates S., Zografi G., Engers D., Morris K., Crowley K., Newman A. Analysis of amorphous and nanocrystalline solids from their X-ray diffraction patterns. Pharm. Res. 2006, 23:2333-2349.
24. Dijiba Y.K., Zhang A., Niemczyk T.M. Determinations of ephedrine in mixtures of ephedrine and pseudoephedrine using diffuse reflectance infrared spectroscopy. Int. J. Pharm. 2005, 289:39-49.
25. Karjalainen M., Airaksinen S., Rantanen J., Aaltonen J., Yliruusi J. Characterization of polymorphic solid-state changes using variable temperature X-ray powder diffraction. J. Pharm. Biomed. Anal. 2005, 39:27-32.
26. Higgins J.P., Arrivo S.M., Reed R.A. Approach to the determination of hydrate form conversions of drug compounds and solid dosage forms by near-infrared spectroscopy. J. Pharm. Sci. 2003, 92:2303-2316.
27. Skoulika S.G., Georgiou C.A. Rapid, noninvasive quantitative determination of acyclovir in pharmaceutical solid dosage forms through their poly(vinyl chloride) blister package by solid-state Fourier transform Raman spectroscopy. Appl. Spectrosc. 2003, 57:407-412.
28. Skoulika S.G., Georgiou C.A. Rapid quantitative determination of ciprofloxacin in pharmaceuticals by use of solid-state FT-Raman spectroscopy. Appl. Spectrosc. 2001, 55:1259-1265.
29. Patel A.D., Luner P.E., Kemper M.S. Quantitative analysis of polymorphs in binary and multi-component powder mixtures by near-infrared reflectance spectroscopy. Int. J. Pharm. 2000, 206:63-74.
30. Shete G., Puri V., Kumar L., Bansal A.K. Solid state characterization of commercial crystalline and amorphous atorvastatin calcium samples. AAPS PharmSciTech 2010, 11:598-609.
31. Windbergs M., Haaser M., McGoverin C.M., Gordon K.C., Kleinebudde P., Strachan C.J. Investigating the relationship between drug distribution in solid lipid matrices and dissolution behaviour using Raman spectroscopy and mapping. J. Pharm. Sci. 2010, 99:1464-1475.
32. Monajjemzadeh F., Hassanzadeh D., Valizadeh H., Siahi-Shadbad M.R., Mojarrad J.S., Robertson T.A., Roberts M.S. Compatibility studies of acyclovir and lactose in physical mixtures and commercial tablets. Eur. J. Pharm. Biopharm. 2009, 73:404-413.
33. Araújo A.A.S., Storpirtis S., Mercuri L.P., Carvalho F.M.S., Filho M.d.S., Matos J.R. Thermal analysis of the antiretroviral zidovudine (AZT) and evaluation of the compatibility with excipients used in solid dosage forms. Int. J. Pharm. 2003, 260:303-314.
34. Hu Y., Wikström H., Byrn S.R., Taylor L.S. Estimation of the transition temperature for an enantiotropic polymorphic system from the transformation kinetics monitored using Raman spectroscopy. J. Pharm. Biomed. Anal. 2007, 45:546-551.
35. Lee E.H., Boerrigter S.X.M., Rumondor A.C.F., Chamarthy S.P., Byrn S.R. Formation and solid-state characterization of a salt-induced metastable polymorph of flufenamic acid. Cryst. Growth Des. 2008, 8:91-97.
36. Dharmayat S., Calderon De Anda J., Hammond R.B., Lai X., Roberts K.J., Wang X.Z. Polymorphic transformation of l-glutamic acid monitored using combined on-line video microscopy and X-ray diffraction. J. Cryst. Growth 2006, 294:35-40.
37. Upadhya P.C., Nguyen K.L., Shen Y.C., Obradovic J., Fukushige K., Griffiths R., Gladden L.F., Davies A.G., Linfield E.H. Characterization of crystalline phase transformations in theophylline by time-domain terahertz spectroscopy. Spectrosc. Lett. 2006, 39:215-224.
38. Martins F.T., Legendre A.O., Honorato S.B., Ayala A.P., Doriguetto A.n.C., Ellena J. Solvothermal preparation of drug crystals: didanosine. Cryst. Growth Des. 2010, 10:1885-1891.
39. Perumal R., Moorthy Babu S. Synthesis, growth and characterization of an organometallic complex tri-allylthiourea cadmium bromide single crystals. Curr. Appl. Phys. 2010, 10:858-865.
40. Zeitler J.A., Taday P.F., Newnham D.A., Pepper M., Gordon K.C., Rades T. Terahertz pulsed spectroscopy and imaging in the pharmaceutical setting a review. J. Pharm. Pharmacol. 2007, 59:209-223.
41. Strachan C.J., Taday P.F., Newnham D.A., Gordon K.C., Zeitler J.A., Pepper M., Rades T. Using terahertz pulsed spectroscopy to quantify pharmaceutical polymorphism and crystallinity. J. Pharm. Sci. 2005, 94:837-846.
42. Zeitler J.A., Newnham D.A., Taday P.F., Threlfall T.L., Lancaster R.W., Berg R.W., Strachan C.J., Pepper M., Gordon K.C., Rades T. Characterization of temperature-induced phase transitions in five polymorphic forms of sulfathiazole by terahertz pulsed spectroscopy and differential scanning calorimetry. J. Pharm. Sci. 2006, 95:2486-2498.
43. De Villiers M.M., Terblanche R.J., Liebenberg W., Swanepoel E., Dekker T.G., Song M. Variable-temperature X-ray powder diffraction analysis of the crystal transformation of the pharmaceutically preferred polymorph C of mebendazole. J. Pharm. Biomed. Anal. 2005, 38:435-441.
44. Zeitler J.A., Newnham D.A., Taday P.F., Strachan C.J., Pepper M., Gordon K.C., Rades T. Temperature dependent terahertz pulsed spectroscopy of carbamazepine. Thermochim. Acta 2005, 436:71-77.
45. Murnane D., Marriott C., Martin G.P. Polymorphic control of inhalation microparticles prepared by crystallization. Int. J. Pharm. 2008, 361:141-149.
46. Cheng W.-T., Lin S.-Y., Wang S.-L. Differential scanning calorimetry with curve-fitting program used to quantitatively analyze the polymorphic transformation of famotidine in the compressed compact. Drug Dev. Ind. Pharm. 2008, 34:1368-1375.
47. Chieng N., Zujovic Z., Bowmaker G., Rades T., Saville D. Effect of milling conditions on the solid-state conversion of ranitidine hydrochloride form 1. Int. J. Pharm. 2006, 327:35-44.
48. Vernuri N.M., Chrzan Z., Gavatur R. Use of isothermal microcalorimetry in pharmaceutical preformulation studies. Part I. Monitoring crystalline phase transitions. J. Therm. Anal. Calorim. 2004, 78:47-54.
49. Abu Bakar M.R., Nagy Z., Rielly C. A combined approach of differential scanning calorimetry and hot-stage microscopy with image analysis in the investigation of sulfathiazole polymorphism. J. Therm. Anal. Calorim. 2010, 99:609-619.
50. Novoa de Armas H., Peeters O.M., Van den Mooter G., Blaton N. Polymorphism of alprazolam (Xanax®): a review of its crystalline phases and identification, crystallographic characterization, and crystal structure of a new polymorph (form III). J. Pharm. Sci. 2007, 96:1114-1130.
51. Lin S.-Y., Cheng W.-T., Wang S.-L. Thermodynamic and kinetic characterization of polymorphic transformation of famotidine during grinding. Int. J. Pharm. 2006, 318:86-91.
52. Wang S.-L., Lin S.-Y., Wei Y.-S. Transformation of metastable forms of acetaminophen studied by thermal Fourier transform infrared (FT-IR) microspectroscopy. Chem. Pharm. Bull. 2002, 50:153-156.
53. Kogermann K., Aaltonen J., Strachan C.J., Pöllänen K., Heinämäki J., Yliruusi J., Rantanen J. Establishing quantitative in-line analysis of multiple solid-state transformations during dehydration. J. Pharm. Sci. 2008, 97:4983-4999.
54. Kogermann K., Aaltonen J., Strachan C.J., Pöllänen K., Veski P., Heinämäki J., Yliruusi J., Rantanen J. Qualitative in situ analysis of multiple solid-state forms using spectroscopy and partial least squares discriminant modeling. J. Pharm. Sci. 2007, 96:1802-1820.
55. Newman A., Engers D., Bates S., Ivanisevic I., Kelly R.C., Zografi G. Characterization of amorphous API:polymer mixtures using X-ray powder diffraction. J. Pharm. Sci. 2008, 97:4840-4856.
56. Petkov V., Billinge S.J.L., Heising J., Kanatzidis M.G. Application of atomic pair distribution function analysis to materials with intrinsic disorder. Three-dimensional structure of exfoliated-restacked WS2: not just a random turbostatic assembly of layers. J. Am. Chem. Soc. 2000, 122:11571-11576.
57. Heinz A., Strachan C.J., Atassi F., Gordon K.C., Rades T. Characterizing an amorphous system exhibiting trace crystallinity: a case study with saquinavir. Cryst. Growth Des. 2007, 8:119-127.
58. Lehto V.-P., Tenho M., Vaha-Heikkila K., Harjunen P., Paallysaho M., Valisaari J., Niemela P., Jarvinen K. The comparison of seven different methods to quantify the amorphous content of spray dried lactose. Powder Technol. 2006, 167:85-93.
59. Chieng N., Rades T., Saville D. Formation and physical stability of the amorphous phase of ranitidine hydrochloride polymorphs prepared by cryo-milling. Eur. J. Pharm. Biopharm. 2008, 68:771-780.
60. Zhang F., Aaltonen J., Tian F., Saville D.J., Rades T. Influence of particle size and preparation methods on the physical and chemical stability of amorphous simvastatin. Eur. J. Pharm. Biopharm. 2009, 71:64-70.
61. Gusseme A.D., Neves C., Willart J.F., Rameau A., Descamps M. Ordering and disordering of molecular solids upon mechanical milling: the case of fananserine. J. Pharm. Sci. 2008, 97:5000-5012.
62. Abdul-Fattah A.M., Dellerman K.M., Bogner R.H., Pikal M.J. The effect of annealing on the stability of amorphous solids: chemical stability of freeze-dried moxalactam. J. Pharm. Sci. 2007, 96:1237-1250.
63. Bhugra C., Shmeis R., Krill S.L., Pikal M.J. Prediction of onset of crystallization from experimental relaxation times. II. Comparison between predicted and experimental onset times. J. Pharm. Sci. 2008, 97:455-472.
64. Allesø M., Chieng N., Rehder S., Rantanen J., Rades T., Aaltonen J. Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: amorphous naproxen-cimetidine mixtures prepared by mechanical activation. J. Control. Release 2009, 136:45-53.
65. Chieng N., Aaltonen J., Saville D., Rades T. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation. Eur. J. Pharm. Biopharm. 2009, 71:47-54.
66. Shimpi S., Mahadik K., Takada K., Paradkar A. Application of polyglycolized glycerides in protection of amorphous form of etoricoxib during compression. Chem. Pharm. Bull. 2007, 55:1448-1451.
67. Strydom S., Liebenberg W., Yu L., de Villiers M. The effect of temperature and moisture on the amorphous-to-crystalline transformation of stavudine. Int. J. Pharm. 2009, 379:72-81.
68. Kauffman J.F., Batykefer L.M., Tuschel D.D. Raman detected differential scanning calorimetry of polymorphic transformations in acetaminophen. J. Pharm. Biomed. Anal. 2008, 48:1310-1315.
69. Qi S., Avalle P., Saklatvala R., Craig D.Q.M. An investigation into the effects of thermal history on the crystallisation behaviour of amorphous paracetamol. Eur. J. Pharm. Biopharm. 2008, 69:364-371.
70. Savolainen M., Kogermann K., Heinz A., Aaltonen J., Peltonen L., Strachan C., Yliruusi J. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy. Eur. J. Pharm. Biopharm. 2009, 71:71-79.
71. De Beer T.R.M., Wiggenhorn M., Veillon R., Debacq C., Mayeresse Y., Moreau B., Burggraeve A., Quinten T., Friess W., Winter G., Vervaet C., Remon J.P., Baeyens W.R.G. Importance of using complementary process analyzers for the process monitoring, analysis, and understanding of freeze drying. Anal. Chem. 2009, 81:7639-7649.
72. Romero-Torres S., Wikström H., Grant E.R., Taylor L.S. Monitoring of mannitol phase behavior during freeze-drying using non-invasive Raman spectroscopy. PDA J. Pharm. Sci. Technol. 2007, 61:131-145.
73. Telang C., Suryanarayanan R. Crystallization of cephalothin sodium during lyophilization from tert-butyl alcohol-water cosolvent system. Pharm. Res. 2005, 22:153-160.
74. Okumura T., Ishida M., Takayama K., Otsuka M. Polymorphic transformation of indomethacin under high pressures. J. Pharm. Sci. 2006, 95:689-700.
75. Chieng N., Rehder S., Saville D., Rades T., Aaltonen J. Quantitative solid-state analysis of three solid forms of ranitidine hydrochloride in ternary mixtures using Raman spectroscopy and X-ray powder diffraction. J. Pharm. Biomed. Anal. 2009, 49:18-25.
76. Heinz A., Savolainen M., Rades T., Strachan C.J. Quantifying ternary mixtures of different solid-state forms of indomethacin by Raman and near-infrared spectroscopy. Eur. J. Pharm. Sci. 2007, 32:182-192.
77. Kachrimanis K., Braun D.E., Griesser U.J. Quantitative analysis of paracetamol polymorphs in powder mixtures by FT-Raman spectroscopy and PLS regression. J. Pharm. Biomed. Anal. 2007, 43:407-412.
78. Kojima T., Yamauchi Y., Onoue S., Tsuda Y. Evaluation of hydrate formation of a pharmaceutical solid by using diffuse reflectance infrared Fourier-transform spectroscopy. J. Pharm. Biomed. Anal. 2008, 46:788-791.
79. Suihko E., Lehto V.-P., Ketolainen J., Laine E., Paronen P. Dynamic solid-state and tableting properties of four theophylline forms. Int. J. Pharm. 2001, 217:225-236.
80. Mirza S., Heinämäki J., Miroshnyk I., Rantanen J., Christiansen L., Karjalainen M., Yliruusi J. Understanding processing-induced phase transformations in erythromycin-PEG 6000 solid dispersions. J. Pharm. Sci. 2006, 95:1723-1732.
81. Zimmermann A., Tian F., Lopez de Diego H., Ringkjøbing Elema M., Rantanen J., Müllertz A., Hovgaard L. Influence of the solid form of siramesine hydrochloride on its behavior in aqueous environments. Pharm. Res. 2009, 26:846-854.
82. Tian F., Zhang F., Sandler N., Gordon K.C., McGoverin C.M., Strachan C.J., Saville D.J., Rades T. Influence of sample characteristics on quantification of carbamazepine hydrate formation by X-ray powder diffraction and Raman spectroscopy. Eur. J. Pharm. Biopharm. 2007, 66:466-474.
83. Tian F., Rades T., Sandler N. Visualizing solvent mediated phase transformation behavior of carbamazepine polymorphs by principal component analysis. AAPS PharmSciTech 2008, 9:390-394.
84. Lehto P., Aaltonen J., Niemelä P., Rantanen J., Hirvonen J., Tanninen V.P., Peltonen L. Simultaneous measurement of liquid-phase and solid-phase transformation kinetics in rotating disc and channel flow cell dissolution devices. Int. J. Pharm. 2008, 363:66-72.
85. Airaksinen S., Luukkonen P., Jørgensen A., Karjalainen M., Rantanen J., Yliruusi J. Effects of excipients on hydrate formation in wet masses containing theophylline. J. Pharm. Sci. 2003, 92:516-528.
86. Kim Y.-S., Paskow H.C., Rousseau R.W. Propagation of solid-state transformations by dehydration and stabilization of pseudopolymorphic crystals of sodium naproxen. Cryst. Growth Des. 2005, 5:1623-1632.
87. Mallet F., Petit S., Lafont S., Billot P., Lemarchand D., Coquerel G. Solvent exchanges among molecular compounds. J. Therm. Anal. Calorim. 2003, 73:459-471.
88. Fujii K., Uekusa H., Itoda N., Hasegawa G., Yonemochi E., Terada K., Pan Z., Harris K.D.M. Physicochemical understanding of polymorphism and solid-state dehydration/rehydration processes for the pharmaceutical material acrinol, by Ab initio powder X-ray diffraction analysis and other techniques. J. Phys. Chem. C 2010, 114:580-586.
89. Miroshnyk I., Khriachtchev L., Mirza S., Rantanen J., Heinämäki J., Yliruusi J. Insight into thermally induced phase transformations of erythromycin A dihydrate. Cryst. Growth Des. 2006, 6:369-374.
90. Räsänen E., Rantanen J., Mannermaa J.-P., Yliruusi J., Vuorela H. Dehydration studies using a novel multichamber microscale fluid bed dryer with in-line near-infrared measurement. J. Pharm. Sci. 2003, 92:2074-2081.
91. Wikström H., Marsac P.J., Taylor L.S. In-line monitoring of hydrate formation during wet granulation using Raman spectroscopy. J. Pharm. Sci. 2005, 94:209-219.
92. Chen Z.-P., Fevotte G., Caillet A., Littlejohn D., Morris J. Advanced calibration strategy for in situ quantitative monitoring of phase transition processes in suspensions using FT-Raman spectroscopy. Anal. Chem. 2008, 80:6658-6665.
93. Qu H., Louhi-Kultanen M., Rantanen J., Kallas J. Solvent-mediated phase transformation kinetics of an anhydrate/hydrate system. Cryst. Growth Des. 2006, 6:2053-2060.
94. Gift A.D., Taylor L.S. Hyphenation of Raman spectroscopy with gravimetric analysis to interrogate water-solid interactions in pharmaceutical systems. J. Pharm. Biomed. Anal. 2007, 43:14-23.
95. Childs S.L., Zaworotko M.J. The reemergence of cocrystals: the crystal clear writing is on the wall introduction to virtual special issue on pharmaceutical cocrystals. Cryst. Growth Des. 2009, 9:4208-4211.
96. Sekhon B. Pharmaceutical co-crystals - a review. ARS Pharm. 2009, 50:99-117.
97. Padrela L., Rodrigues M.A., Velaga S.P., Matos H.A., de Azevedo E.G. Formation of indomethacin-saccharin cocrystals using supercritical fluid technology. Eur. J. Pharm. Sci. 2009, 38:9-17.
98. Herrmann M., Förter-Barth U., Kröber H., Kempa P.B., Juez-Lorenzo M.d.M., Doyle S. Co-crystallization and characterization of pharmaceutical ingredients. Part. Part. Syst. Char. 2009, 26:151-156.
99. Maheshwari C., Jayasankar A., Khan N.A., Amidon G.E., Rodríguez-Hornedo N. Factors that influence the spontaneous formation of pharmaceutical cocrystals by simply mixing solid reactants. CrystEngComm 2009, 11:493-500.
100. Gagnière E., Mangin D., Puel F., Rivoire A., Monnier O., Garcia E., Klein J.P. Formation of co-crystals: kinetic and thermodynamic aspects. J. Cryst. Growth 2009, 311:2689-2695.
101. Porter W.W., Elie S.C., Matzger A.J. Polymorphism in carbamazepine cocrystals. Cryst. Growth Des. 2008, 8:14-16.
102. Takata N., Takano R., Uekusa H., Hayashi Y., Terada K. A spironolactone-saccharin 1:1 cocrystal hemihydrate. Cryst. Growth Des. 2010, 10:2116-2122.
103. Karki S., Friščić T., Jones W., Motherwell W.D.S. Screening for pharmaceutical cocrystal hydrates via neat and liquid-assisted grinding. Mol. Pharm. 2007, 4:347-354.
104. Bhatt P.M., Azim Y., Thakur T.S., Desiraju G.R. Co-crystals of the anti-HIV drugs lamivudine and zidovudine. Cryst. Growth Des. 2008, 9:951-957.
105. Pop M., Sieger P., Cains P.W. Tiotropium fumarate: an interesting pharmaceutical co-crystal. J. Pharm. Sci. 2009, 98:1820-1834.
106. Velaga S.P., Basavoju S., Boström D. Norfloxacin saccharinate-saccharin dihydrate cocrystal - a new pharmaceutical cocrystal with an organic counter ion. J. Mol. Struct. 2008, 889:150-153.
107. Chieng N., Hubert M., Saville D., Rades T., Aaltonen J. Formation kinetics and stability of carbamazepine-nicotinamide cocrystals prepared by mechanical activation. Cryst. Growth Des. 2009, 9:2377-2386.
108. Liao X., Gautam M., Grill A., Zhu H.J. Effect of position isomerism on the formation and physicochemical properties of pharmaceutical co-crystals. J. Pharm. Sci. 2010, 99:246-254.
109. Jayasankar A., Somwangthanaroj A., Shao Z., Rodríguez-Hornedo N. Cocrystal formation during cogrinding and storage is mediated by amorphous phase. Pharm. Res. 2006, 23:2381-2392.
110. McNamara D., Childs S., Giordano J., Iarriccio A., Cassidy J., Shet M., Mannion R., O'Donnell E., Park A. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharm. Res. 2006, 23:1888-1897.
111. Parrott E.P.J., Zeitler J.A., Friščić T., Day G.M., Pepper M., Jones W., Gladden L.F. 33rd International Conference on Infrared and Millimeter Waves and the 16th International Conference on Terahertz Electronics, 2008, IRMMW-THz 2008 2008.
112. Bučar D.-K., Henry R.F., Lou X., Duerst R.W., Borchardt T.B., MacGillivray L.R., Zhang G.G.Z. Co-crystals of caffeine and hydroxy-2-naphthoic acids: unusual formation of the carboxylic acid dimer in the presence of a heterosynthon. Mol. Pharm. 2007, 4:339-346.
113. Allesø M., Velaga S., Alhalaweh A., Cornett C., Rasmussen M.A., Berg F.v.d., Diego H.L.d., Rantanen J. Near-infrared spectroscopy for cocrystal screening. A comparative study with Raman spectroscopy. Anal. Chem. 2008, 80:7755-7764.
114. Parrott E.P.J., Zeitler J.A., Friščić T., Pepper M., Jones W., Day G.M., Gladden L.F. Testing the sensitivity of terahertz spectroscopy to changes in molecular and supramolecular structure: a study of structurally similar cocrystal. Cryst. Growth Des. 2009, 9:1452-1460.
115. Seefeldt K., Miller J., Alvarez-Núñez F., Rodríguez-Hornedo N. Crystallization pathways and kinetics of carbamazepine-nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy, and calorimetry studies. J. Pharm. Sci. 2007, 96:1147-1158.
116. Berry D.J., Seaton C.C., Clegg W., Harrington R.W., Coles S.J., Horton P.N., Hursthouse M.B., Storey R., Jones W., Friščić T., Blagden N. Applying hot-stage microscopy to co-crystal screening: a study of nicotinamide with seven active pharmaceutical ingredients. Cryst. Growth Des. 2008, 8:1697-1712.
117. Brittain H.G. Spectroscopy of Pharmaceutical Solids 2006, Taylor & Francis Group, New York. 1st ed.
118. Forster A., Gordon K., Schmierer D., Soper N., Wu V., Rades T. Characterisation of two polymorphic forms of ranitidine-HCl. Internet J. Vib. Spectrosc. 1998, 2.
119. Bugay D.E. Characterization of the solid state: spectroscopic techniques. Adv. Drug Deliv. Rev. 2001, 48:43-65.
120. Colthup N.B., Daly L.H., Wiberley S.E. Introduction to Infrared and Raman Spectroscopy 1990, Academic Press, Inc., San Diego. 3rd ed.
121. Wartewig S., Neubert R.H.H. Pharmaceutical applications of mid-IR and Raman spectroscopy. Adv. Drug Deliv. Rev. 2005, 57:1144-1170.
122. Chalmers J.M., Everall N.J. FTIR, FT-Raman and chemometrics: applications to the analysis and characterisation of polymers. Trends Anal. Chem. 1996, 15:18-25.
123. Petty C.J., Bugay D.E., Findlay W.P., Rodriquez C. Applications of FT-Raman spectroscopy in the pharmaceutical industry. Spectroscopy 1996, 11:41-45.
124. McGoverin C.M., Rades T., Gordon K.C. Recent pharmaceutical applications of Raman and terahertz spectroscopies. J. Pharm. Sci. 2008, 97:4598-4621.
125. Komyak A.I., Malyarevich A.M., Posledovich M.P. Raman spectroscopy study of hydrogen bonds and vibrations of the triglycine sulfate crystal lattice. J. Appl. Spectrosc. 1993, 59:832-836.
126. Small G.W. Chemometrics and near-infrared spectroscopy: avoiding the pitfalls. Trends Anal. Chem. 2006, 25:1057-1066.
127. Räsänen E., Sandler N. Near infrared spectroscopy in the development of solid dosage forms. J. Pharm. Pharmacol. 2006, 59:147-159.
128. Reich G. Near-infrared spectroscopy and imaging: basic principles and pharmaceutical applications. Adv. Drug Deliv. Rev. 2005, 57:1109-1143.
129. Elizarova T., Shtyleva S., Pleteneva T. Using near-infrared spectrophotometry for the identification of pharmaceuticals and drugs. Pharm. Chem. J. 2008, 42:432-434.
130. Tishmack P.A., Bugay D.A., Byrn S.R. Solid-state nuclear magnetic resonance spectroscopy - pharmaceutical application. J. Pharm. Sci. 2003, 92:441-474.
131. Offerdahl T.J. Solid-state NMR spectroscopy for pharmaceutical analysis. Pharm. Technol. 2004, 28:S54.
132. Berendt R.T., Sperger D.M., Munson E.J., Isbester P.K. Solid-state NMR spectroscopy in pharmaceutical research and analysis. Trends Anal. Chem. 2006, 25:977-984.
133. Taday P.F. Applications of terahertz spectroscopy to pharmaceutical sciences, philosophical transactions: mathematical. Phys. Eng. Sci. 2004, 362:351-364.
134. Newnham D.A., Taday P.F. Pulsed terahertz attenuated total reflection spectroscopy. Appl. Spectrosc. 2008, 62:394-398.
135. Brügemann L., Gerndt E.K.E. Detectors for X-ray diffraction and scattering: a user's overview. Nucl. Instrum. Methods Phys. Res., Sect. A 2004, 531:292-301.
136. Hemley R.J., Chiarotti G.L., Bernasconi M., Ulivi L. High Pressure Phenomena 2002, IOS Press, Italy.
137. Harris K.D.M. Modern applications of powder X-ray diffraction in pharmaceutical sciences. Am. Pharm. Rev. 2004, 7:86-91.
138. Roe R.-J. Methods of X-ray and Neutron Scattering in Polymer Science 2000, Oxford University Press, New York.
139. Chu B., Hsiao B.S. Small-angle X-ray scattering of polymers. Chem. Rev. 2001, 101:1727-1761.
140. Wutz C., Bark M., Cronauer J., Diihrmann R., Zachmann H.G. Simultaneous measurements of small angle X-ray scattering, wide angle X-ray scattering, and light scattering during phase transitions in polymers (invited). Rev. Sci. Instrum. 1995, 66:1303-1307.
141. Craig D., Reading M. Principles of differential scanning calorimetry. Thermal Analysis of Pharmaceuticals 2007, CRC Press, Taylor and Francis Group, Boca Raton, FL. D. Craig, M. Reading (Eds.).
142. Ford J., Timmins P. Pharmaceutical Thermal Analysis: Techniques and Applications 1989, Ellis Horwood Limited, Chichester, West Sussex, England.
143. Craig D.M.Q., Royall P.G. The use of modulated temperature DSC for the study of pharmaceutical systems: potential uses and limitation. Pharm. Res. 1998, 15:1152-1153.
144. Verdonck E., Schaap K., Thomas L.C. A discussion of the principles and application of modulated temperature DSC (MTDSC). Int. J. Pharm. 1999, 192:3-20.
145. Royall P.G., Craig D.Q.M., Doherty C. Characterisation of moisture uptake effects on the glass transitional behaviour of an amorphous drug using modulated temperature DSC. Int. J. Pharm. 1999, 192:39-46.
146. Han J., Suryanarayanan R. A method for the rapid evaluation of the physical stability of pharmaceutical hydrates. Thermochim. Acta 1999, 329:163-170.
147. Galwey A., Craig D. Thermogravimetric analysis: basic principles. Thermal Analysis of Pharmaceuticals 2007, 139-192. CRC Press, Taylor and Francis Group, Boca Raton, FL. D. Craig, M. Reading (Eds.).
148. Willson R. Calorimetry. Principles of Thermal Analysis and Calorimetry 2002, Royal Society of Chemistry, Cambridge, UK. P.J. Haines (Ed.).
149. Kemp R. Nonscanning calorimetry. Handbook of Thermal Analysis and Calorimetry: Principles and Practice 1998, Elsevier Science B.V., Amsterdam, The Netherlands. M.E. Brown (Ed.).
150. Buckton G. Principles and pharmaceutical applications of isothermal microcalorimetry. Thermal Analysis of Pharmaceuticals 2007, 265-286. CRC Press, Taylor and Francis Group, Boca Raton, FL. D. Craig, M. Reading (Eds.).
151. Wadsö I. Trends in isothermal microcalorimetry. Chem. Soc. Rev. 1997, 26:79-86.
152. Gaisford S., O'Neill M.A.A. Pharmaceutical Isothermal Calorimetry 2007, Informa Healthcare USA, Inc., New York, NY.
153. Gao D., Rytting J.H. Use of solution calorimetry to determine the extent of crystallinity of drugs and excipients. Int. J. Pharm. 1997, 151:183-192.
154. Price R., Young P.M. Visualization of the crystallization of lactose from the amorphous state. J. Pharm. Sci. 2004, 93:155-164.
155. Lu J., Rohani S. Preparation and characterization of theophylline-nicotinamide cocrystal. Org. Process Res. Dev. 2009, 13:1269-1275.
156. Liu J. Physical characterization of pharmaceutical formulation in frozen and freeze-dried solid states: techniques and applications in freeze-drying development. Pharm. Dev. Technol. 2006, 11:3-28.
157. May J.C., Grim E., Wheeler R.M., West J. Determination of residual moisture in freeze-dried viral vaccines: Karl Fischer, gravimetric and thermogravimetric methodologies. J. Biol. Stand. 1982, 10:249-259.
158. Zhu L., Chen Y., Gao Y.-Y., Wang J.-K. Determination of total water content in tobramycin using the volumetric Karl Fischer titration. Chin. J. Antibiot. 2008, 33. 753-755, 760.
159. Vippagunta R.R., Pan C., Vakil R., Meda V., Vivilecchia R., Motto M. Application of surface area measurement for identifying the source of batch-to-batch variation in processability. Pharm. Dev. Technol. 2009, 14:492-498.
160. Lowell S., Shields J.E. Powder Surface Area and Porosity 1984, J.W. Arrowsmith Ltd., Bristol, Great Britain.
161. Katrincic L.M., Sun Y.T., Carlton R.A., Diederich A.M., Mueller R.L., Vogt F.G. Characterization, selection, and development of an orally dosed drug polymorph from an enantiotropically related system. Int. J. Pharm. 2009, 366:1-13.
162. Foppoli A., Zema L., Gazzaniga A., Caira M.R., Nassimbeni L.R., Borkum E., Bettini R., Giordano F. Solid-state chemistry of ambroxol theophylline-7-acetate. J. Pharm. Sci. 2007, 96:1139-1146.
163. Rastogi S., Zakrzewski M., Suryanarayanan R. Investigation of solid-state reactions using variable temperature X-ray powder diffractometry. II. Aminophylline monohydrate. Pharm. Res. 2002, 19:1265-1273.
164. Goddeeris C., Willems T., Houthoofd K., Martens J.A., Van den Mooter G. Dissolution enhancement of the anti-HIV drug UC 781 by formulation in a ternary solid dispersion with TPGS 1000 and Eudragit E100. Eur. J. Pharm. Biopharm. 2008, 70:861-868.
165. Mirza S., Miroshnyk I., Rantanen J., Aaltonen J., Harjula P., Kiljunen E., Heinämäki J., Yliruusi J. Solid-state properties and relationship between anhydrate and monohydrate of baclofen. J. Pharm. Sci. 2007, 96:2399-2408.
166. De Spiegeleer B., Seghers D., Wieme R., Schaubroeck J., Verpoort F., Slegers G., Van Vooren L. Determination of the relative amounts of three crystal forms of a benzimidazole drug in complex finished formulations by FT-Raman spectroscopy. J. Pharm. Biomed. Anal. 2005, 39:275-280.
167. Tong H.H.Y., Chow A.S.F., Chan H.M., Chow A.H.L., Wan Y.K.Y., Williams I.D., Shek F.L.Y., Chan C.K. Process-induced phase transformation of berberine chloride hydrates. J. Pharm. Sci. 2010, 99:1942-1954.
168. Lemmerer A., Baì·thori N.B., Esterhuysen C., Bourne S.A., Caira M.R. Concomitant polymorphs of the antihyperlipoproteinemic bezafibrate. Cryst. Growth Des. 2009, 9:2646-2655.
169. McArdle P., Gilligan K., Cunningham D., Ryder A. Determination of the polymorphic forms of bicifadine hydrochloride by differential scanning calorimetry, thermogravimetric analysis, X-ray powder diffraction, attenuated total reflectance-infrared spectroscopy and attenuated total reflectance-near-infrared spectroscopy. Appl. Spectrosc. 2005, 59:1365-1371.
170. Jug M., Maestrelli F., Bragagni M., Mura P. Preparation and solid-state characterization of bupivacaine hydrochloride cyclodextrin complexes aimed for buccal delivery. J. Pharm. Biomed. Anal. 2010, 52:9-18.
171. Hugerth A., Brisander M., Wrange U., Kritikos M., Norrlind B., Svensson M., Bisrat M., Ostelius J. Physical characterization of anhydrous and hydrous forms of the hydrochloride salt of BVT.5182 A novel 5-HT 6 receptor antagonist. Drug Dev. Ind. Pharm. 2006, 32:185-196.
172. Lehto P., Aaltonen J., Tenho M., Rantanen J., Hirvonen J., Tanninen V.P., Peltonen L. Solvent-mediated solid phase transformations of carbamazepine: effects of simulated intestinal fluid and fasted state simulated intestinal fluid. J. Pharm. Sci. 2009, 98:985-996.
173. Tian F., Sandler N., Aaltonen J., Lang C., Saville D., Gordon K.C., Strachan C.J., Rantanen J., Rades T. Influence of polymorphic form, morphology, and excipient interactions on the dissolution of carbamazepine compacts. J. Pharm. Sci. 2007, 96:584-594.
174. Chawla G., Gupta P., Thilagavathi R., Chakraborti A.K., Bansal A.K. Characterization of solid-state forms of celecoxib. Eur. J. Pharm. Sci. 2003, 20:305-317.
175. Wildfong P.L.D., Morris K.R., Anderson C.A., Short S.M. Demonstration of a shear-based solid-state phase transformation in a small molecular organic system: chlorpropamide. J. Pharm. Sci. 2007, 96:1100-1113.
176. Otsuka M., Kato F., Matsuda Y. Physicochemical stability of cimetidine amorphous forms estimated by isothermal microcalorimetry. AAPS PharmSciTech 2002, 3:E30.
177. Tantishaiyakul V., Suknuntha K., Vao-Soongnern V. Characterization of cimetidine-piroxicam coprecipitate interaction using experimental studies and molecular dynamic simulations. AAPS PharmSciTech 2010, doi:10.1208/s12249-12010-19461-12245.
178. Tozuka Y., Ito A., Seki H., Oguchi T., Yamamoto K. Characterization and quantitation of clarithromycin polymorphs by powder X-ray diffractometry and solid-state NMR spectroscopy. Chem. Pharm. Bull. 2002, 50:1128-1130.
179. Vittorio B., Elena P., Riccardo S., Fabio S. Quantitative determination of amorphous cyclosporine in crystalline cyclosporine samples by Fourier transform infrared spectroscopy. J. Pharm. Sci. 2006, 95:159-166.
180. Jadhav G.S., Vavia P.R. Physicochemical, in silico and in vivo evaluation of a danazol-[beta]-cyclodextrin complex. Int. J. Pharm. 2008, 352:5-16.
181. Bartolomei M., Rodomonte A., Antoniella E., Minelli G., Bertocchi P. Hydrate modifications of the non-steroidal anti-inflammatory drug diclofenac sodium: solid-state characterisation of a trihydrate form. J. Pharm. Biomed. Anal. 2007, 45:443-449.
182. Martínez-Ohárriz M.C., Rodríguez-Espinosa C., Martín C., Goñi M.M., Tros-Ilarduya M.C., Sánchez M. Solid dispersions of diflunisal-PVP: polymorphic and amorphous states of the drug. Drug Dev. Ind. Pharm. 2002, 28:717-725.
183. Patterson J.E., James M.B., Forster A.H., Lancaster R.W., Butler J.M., Rades T. The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds. J. Pharm. Sci. 2005, 94:1998-2012.
184. Sathigari S., Chadha G., Lee Y.H., Wright N., Parsons D., Rangari V., Fasina O., Babu R. Physicochemical characterization of efavirenz-cyclodextrin inclusion complexes. AAPS PharmSciTech 2009, 10:81-87.
185. Baronsky J., Bongaerts S., Traeubel M., Weiss H.-C., Urbanetz N. The study of different solid forms of Emodepside. Eur. J. Pharm. Biopharm. 2009, 71:88-99.
186. Kumar L., Amin A., Bansal A.K. Preparation and characterization of salt forms of enalapril. Pharm. Dev. Technol. 2008, 13:345-357.
187. Német Z., Kis G.C., Pokol G., Demeter Á. Quantitative determination of famotidine polymorphs: X-ray powder diffractometric and Raman spectrometric study. J. Pharm. Biomed. Anal. 2009, 49:338-346.
188. Heinz A., Gordon K.C., McGoverin C.M., Rades T., Strachan C.J. Understanding the solid-state forms of fenofibrate - a spectroscopic and computational study. Eur. J. Pharm. Biopharm. 2009, 71:100-108.
189. Othman A., Evans J.S.O., Evans I.R., Harris R.K., Hodgkinson P. Structural study of polymorphs and solvates of finasteride. J. Pharm. Sci. 2007, 96:1380-1397.
190. Chen X., Stowell J.G., Morris K.R., Byrn S.R. Quantitative study of solid-state acid-base reactions between polymorphs of flufenamic acid and magnesium oxide using X-ray powder diffraction. J. Pharm. Biomed. Anal. 2009, 51:866-874.
191. Iannuccelli V., Coppi G., Leo E., Fontana F., Bernabei M. PVP solid dispersions for the controlled release of furosemide from a floating multiple-unit system. Drug Dev. Ind. Pharm. 2000, 26:595-603.
192. Schmidt A.C., Schwarz I. Solid-state characterization of non-stoichiometric hydrates of ester-type local anaesthetics. Part XI. Crystal polymorphism of local anaesthetic drugs. Int. J. Pharm. 2006, 320:4-13.
193. Bogdanova S., Pajeva I., Nikolova P., Tsakovska I., Müller B. Interactions of poly(vinylpyrrolidone) with ibuprofen and naproxen: experimental and modeling studies. Pharm. Res. 2005, 22:806-815.
194. Oberoi L.M., Alexander K.S., Riga A.T. Study of interaction between ibuprofen and nicotinamide using differential scanning calorimetry, spectroscopy, and microscopy and formulation of a fast-acting and possibly better ibuprofen suspension for osteoarthritis patients. J. Pharm. Sci. 2005, 94:93-101.
195. Takehiro O., Masaya I., Kozo T., Makoto O. Polymorphic transformation of indomethacin under high pressures. J. Pharm. Sci. 2006, 95:689-700.
196. Bhugra C., Shmeis R., Krill S.L., Pikal M.J. Different measures of molecular mobility: comparison between calorimetric and thermally stimulated current relaxation times below Tg and correlation with dielectric relaxation times above Tg. J. Pharm. Sci. 2008, 97:4498-4515.
197. Basavoju S., Boström D., Velaga S. Indomethacin-saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization. Pharm. Res. 2008, 25:530-541.
198. Harjunen P., Lehto V.P., Koivisto M., Levonen E., Paronen P., Järvinen K. Determination of amorphous content of lactose samples by solution calorimetry. Drug Dev. Ind. Pharm. 2004, 30:809-815.
199. Zeitler J.A., Kogermann K., Rantanen J., Rades T., Taday P.F., Pepper M., Aaltonen J., Strachan C.J. Drug hydrate systems and dehydration processes studied by terahertz pulsed spectroscopy. Int. J. Pharm. 2007, 334:78-84.
200. Airaksinen S., Karjalainen M., Kivikero N., Westermarck S., Shevchenko A., Rantanen J., Yliruusi J. Excipient selection can significantly affect solid-state phase transformation in formulation during wet granulation. AAPS PharmSciTech (electronic resource) 2005, 6.
201. Xie Y., Cao W., Krishnan S., Lin H., Cauchon N. Characterization of mannitol polymorphic forms in lyophilized protein formulations using a multivariate curve resolution (MCR)-based Raman spectroscopic method. Pharm. Res. 2008, 25:2292-2301.
202. Grohganz H., Fonteyne M., Skibsted E., Falck T., Palmqvist B., Rantanen J. Classification of lyophilised mixtures using multivariate analysis of NIR spectra. Eur. J. Pharm. Biopharm. 2010, 74:406-412.
203. Giannellini V., Bambagiotti-Alberti M., Bartolucci G., Bruni B., Coran S.A., Costantino F., Di Vaira M. Solid-state study of mepivacaine hydrochloride. J. Pharm. Biomed. Anal. 2005, 39:444-454.
204. Mura P., Faucci M.T., Bettinetti G.P. The influence of polyvinylpyrrolidone on naproxen complexation with hydroxypropyl-[beta]-cyclodextrin. Eur. J. Pharm. Sci. 2001, 13:187-194.
205. Mura P., Zerrouk N., Mennini N., Maestrelli F., Chemtob C. Development and characterization of naproxen-chitosan solid systems with improved drug dissolution properties. Eur. J. Pharm. Sci. 2003, 19:67-75.
206. Mura P., Bettinetti G.P., Cirri M., Maestrelli F., Sorrenti M., Catenacci L. Solid-state characterization and dissolution properties of naproxen-arginine-hydroxypropyl-[beta]-cyclodextrin ternary system. Eur. J. Pharm. Biopharm. 2005, 59:99-106.
207. Zerrouk N., Mennini N., Maestrelli F., Chemtob C., Mura P. Comparison of the effect of chitosan and polyvinylpyrrolidone on dissolution properties and analgesic effect of naproxen. Eur. J. Pharm. Biopharm. 2004, 57:93-99.
208. Vippagunta S.R., Maul K.A., Tallavajhala S., Grant D.J.W. Solid-state characterization of nifedipine solid dispersions. Int. J. Pharm. 2002, 236:111-123.
209. Aaltonen J., Strachan C.J., Pöllänen K., Yliruusi J., Rantanen J. Hyphenated spectroscopy as a polymorph screening tool. J. Pharm. Biomed. Anal. 2007, 44:477-483.
210. Rantanen J., Wikström H., Rhea F.E., Taylor L.S. Improved understanding of factors contributing to quantification of anhydrate/hydrate powder mixtures. Appl. Spectrosc. 2005, 59:942-951.
211. Limwikrant W., Higashi K., Yamamoto K., Moribe K. Characterization of ofloxacin-oxalic acid complex by PXRD, NMR, and THz spectroscopy. Int. J. Pharm. 2009, 382:50-55.
212. Reutzel-Edens S.M., Bush J.K., Magee P.A., Stephenson G.A., Byrn S.R. Anhydrates and hydrates of olanzapine: crystallization, solid-state characterization, and structural relationships. Cryst. Growth Des. 2003, 3:897-907.
213. Murakami F.S., Lang K.L., Mendes C., Cruz A.P., Filho M.A.S.C., Silva M.A.S. Physico-chemical solid-state characterization of omeprazole sodium: thermal, spectroscopic and crystallinity studies. J. Pharm. Biomed. Anal. 2009, 49:72-80.
214. Unga J., Matsson P., Mahlin D. Understanding polymer-lipid solid dispersions - the properties of incorporated lipids govern the crystallisation behaviour of PEG. Int. J. Pharm. 2009, 386:61-70.
215. Lien Nguyen K., Friščić T., Day G.M., Gladden L.F., Jones W. Terahertz time-domain spectroscopy and the quantitative monitoring of mechanochemical cocrystal formation. Nat. Mater. 2007, 6:206-209.
216. Sotthivirat S., Lubach J.W., Haslam J.L., Munson E.J., Stella V.J. Characterization of prednisolone in controlled porosity osmotic pump pellets using solid-state NMR spectroscopy. J. Pharm. Sci. 2007, 96:1008-1017.
217. Fini A., Ospitali F., Zoppetti G., Puppini N. ATR/Raman and fractal characterization of HPBCD/progesterone complex solid particles. Pharm. Res. 2008, 25:2030-2040.
218. Zoppetti G., Puppini N., Ospitali F., Fini A. Solid state characterization of progesterone in a freeze dried 1:2 progesterone/HPBCD mixture. J. Pharm. Sci. 2007, 96:1729-1736.
219. Li J., Guo Y., Zografi G. The solid-state stability of amorphous quinapril in the presence of beta-cyclodextrins. J. Pharm. Sci. 2002, 91:229-243.
220. Garg A., Singh S., Rao V.U., Bindu K., Balasubramaniam J. Solid state interaction of raloxifene HCl with different hydrophilic carriers during co-grinding and its effect on dissolution rate. Drug Dev. Ind. Pharm. 2009, 35:455-470.
221. Agrawal S., Ashokraj Y., Bharatam P.V., Pillai O., Panchagnula R. Solid-state characterization of rifampicin samples and its biopharmaceutic relevance. Eur. J. Pharm. Sci. 2004, 22:127-144.
222. Maurin M.B., Vickery R.D., Rabel S.R., Rowe S.M., Everlof J.G., Nemeth G.A., Campbell G.C., Foris C.M. Polymorphism of roxifiban. J. Pharm. Sci. 2002, 91:2599-2604.
223. Varasteh M., Deng Z., Hwang H., Kim Y.J., Wong G.B. Quantitative determination of polymorphic impurity by X-ray powder diffractometry in an OROS® formulation. Int. J. Pharm. 2009, 366:74-81.
224. Ali H.R.H., Edwards H.G.M., Hargreaves M.D., Munshi T., Scowen I.J., Telford R.J. Vibrational spectroscopic characterisation of salmeterol xinafoate polymorphs and a preliminary investigation of their transformation using simultaneous in situ portable Raman spectroscopy and differential scanning calorimetry. Anal. Chim. Acta 2008, 620:103-112.
225. Oliveira P., Stulzer H., Bernardi L., Borgmann S., Cardoso S., Silva M. Sibutramine hydrochloride monohydrate. J. Therm. Anal. Calorim. 2010, 100:277-282.
226. Zimper U., Aaltonen J., McGoverin C., Gordon K., Krauel-Goellner K., Rades T. Quantification of process induced disorder in milled samples using different analytical techniques. Pharmaceutics 2010, 2:30-49.
227. Brandão F., Tagiari M., Silva M., Berti L., Stulzer H. Physical-chemical characterization and quality control of spironolactone raw material samples. Pharm. Chem. J. 2008, 42:368-376.
228. Luner P., Majuru S., Seyer J., Kemper M. Quantifying crystalline form composition in binary powder mixtures using near-infrared reflectance spectroscopy. Pharm. Dev. Technol. 2000, 5:231-246.
229. Pöllänen K., Häkkinen A., Reinikainen S.-P., Rantanen J., Karjalainen M., Louhi-Kultanen M., Nyström L. IR spectroscopy together with multivariate data analysis as a process analytical tool for in-line monitoring of crystallization process and solid-state analysis of crystalline product. J. Pharm. Biomed. Anal. 2005, 38:275-284.
230. Aaltonen J., Rantanen J., Siiriä S., Karjalainen M., Jørgensen A., Laitinen N., Savolainen M., Seitavuopio P., Louhi-Kultanen M., Yliruusi J. Polymorph screening using near-infrared spectroscopy. Anal. Chem. 2003, 75:5267-5273.
231. Yeo S.-D., Kim M.-S., Lee J.-C. Recrystallization of sulfathiazole and chlorpropamide using the supercritical fluid antisolvent process. J. Supercrit. Fluids 2003, 25:143-154.
232. Yamashita K., Nakate T., Okimoto K., Ohike A., Tokunaga Y., Ibuki R., Higaki K., Kimura T. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int. J. Pharm. 2003, 267:79-91.
233. Bauer J., Morley J., Spanton S., Leusen F.J.J., Henry R., Hollis S., Heitmann W., Mannino A., Quick J., Dziki W. Identification, preparation, and characterization of several polymorphs and solvates of terazosin hydrochloride. J. Pharm. Sci. 2006, 95:917-928.
234. Aaltonen J., Kogermann K., Strachan C.J., Rantanen J. In-line monitoring of solid-state transitions during fluidisation. Chem. Eng. Sci. 2007, 62:408-415.
235. Smith E.D.L., Hammond R.B., Jones M.J., Roberts K.J., Mitchell J.B.O., Price S.L., Harris R.K., Apperley D.C., Cherryman J.C., Docherty R. The determination of the crystal structure of anhydrous theophylline by X-ray powder diffraction with a systematic search algorithm, lattice energy calculations, and 13C and 15N solid-state NMR: a question of polymorphism in a given unit cell. J. Phys. Chem. B 2001, 105:5818-5826.
236. Jørgensen A., Rantanen J., Karjalainen M., Khriachtchev L., Räsänen E., Yliruusi J. Hydrate formation during wet granulation studied by spectroscopic methods and multivariate analysis. Pharm. Res. 2002, 19:1285-1291.
237. Aaltonen J., Heinänen P., Peltonen L., Kortejärvi H., Tanninen V.P., Christiansen L., Hirvonen J., Yliruusi J., Rantanen J. In situ measurement of solvent-mediated phase transformations during dissolution testing. J. Pharm. Sci. 2006, 95:2730-2737.
238. Nunes C., Mahendrasingam A., Suryanarayanan R. Investigation of the multi-step dehydration reaction of theophylline monohydrate using 2-dimensional powder X-ray diffractometry. Pharm. Res. 2006, 23:2393-2404.
239. Salameh A.K., Taylor L.S. Physical stability of crystal hydrates and their anhydrates in the presence of excipients. J. Pharm. Sci. 2006, 95:446-461.
240. Vogt F.G., Dell'Orco P.C., Diederich A.M., Su Q., Wood J.L., Zuber G.E., Katrincic L.M., Mueller R.L., Busby D.J., DeBrosse C.W. A study of variable hydration states in topotecan hydrochloride. J. Pharm. Biomed. Anal. 2006, 40:1080-1088.
241. Li N., Zhang Y.-H., Wu Y.-N., Xiong X.-L., Zhang Y.-H. Inclusion complex of trimethoprim with [beta]-cyclodextrin. J. Pharm. Biomed. Anal. 2005, 39:824-829.
242. Giampiero B., Mino R.C., Athos C., Marcello M., Milena S., Carla T. Structure and solid-state chemistry of anhydrous and hydrated crystal forms of the trimethoprim-sulfamethoxypyridazine 1:1 molecular complex. J. Pharm. Sci. 2000, 89:478-489.
243. Furuyama N., Hasegawa S., Hamaura T., Yada S., Nakagami H., Yonemochi E., Terada K. Evaluation of solid dispersions on a molecular level by the Raman mapping technique. Int. J. Pharm. 2008, 361:12-18.
244. Bernardi L., Oliveira P., Murakami F., Silva M., Borgmann S., Cardoso S. Characterization of venlafaxine hydrochloride and compatibility studies with pharmaceutical excipients. J. Therm. Anal. Calorim. 2009, 97:729-733.
245. Roy S., Aitipamula S., Nangia A. Thermochemical analysis of venlafaxine hydrochloride polymorphs 1-5. Cryst. Growth Des. 2005, 5:2268-2276.
246. Ribeiro L., Loftsson T., Ferreira D., Veiga F. Investigation and physicochemical characterization of vinpocetine-sulfobutyl ether β-cyclodextrin binary and ternary complexes. Chem. Pharm. Bull. 2003, 51:914-922.
247. Sautel M., Lépinasse G., Leveiller F. Study of the textural changes occurring during a solid state polymorphic transformation induced by temperature and relative humidity. Colloids Surf. A 2001, 187-188:337-347.
248. Stowell G.W., Behme R.J., Denton S.M., Pfeiffer I., Sancilio F.D., Whittall L.B., Whittle R.R. Thermally-prepared polymorphic forms of cilostazol. J. Pharm. Sci. 2002, 91:2481-2488.
249. Mirmehrabi M., Rohani S., Murthy K.S.K., Radatus B. Characterization of tautomeric forms of ranitidine hydrochloride: thermal analysis, solid-state NMR, X-ray. J. Cryst. Growth 2004, 260:517-526.
250. Miller J.M., Collman B.M., Greene L.R., Grant D.J.W., Blackburn A.C. Identifying the stable polymorph early in the drug discovery-development process. Pharm. Dev. Technol. 2005, 10:291-297.
251. Gong Y., Collman B.M., Mehrens S.M., Lu E., Miller J.M., Blackburn A., Grant D.J.W. Stable-form screening: overcoming trace impurities that inhibit solution-mediated phase transformation to the stable polymorph of sulfamerazine. J. Pharm. Sci. 2008, 97:2130-2144.
252. Ali H.R.H., Edwards H.G.M., Scowen I.J. Insight into thermally induced solid-state polymorphic transformation of sulfathiazole using simultaneous in situ Raman spectroscopy and differential scanning calorimetry. J. Raman Spectrosc. 2009, 40:887-892.
253. Sonoda Y., Hirayama F., Arima H., Yamaguchi Y., Saenger W., Uekama K. Selective crystallization of the metastable form IV polymorph of tolbutamide in the presence of 2,6-di-O-methyl-β-cyclodextrin in aqueous solution. Cryst. Growth Des. 2006, 6:1181-1185.
254. Koivisto M., Heinänen P., Tanninen V., Lehto V.-P. Depth profiling of compression-induced disorders and polymorphic transition on tablet surfaces with grazing incidence X-ray diffraction. Pharm. Res. 2006, 23:813-820.
255. Blanco M., Alcalá M., González J.M., Torras E. Near infrared spectroscopy in the study of polymorphic transformations. Anal. Chim. Acta 2006, 567:262-268.
256. Descamps M., Willart J.F., Dudognon E., Caron V. Transformation of pharmaceutical compounds upon milling and comilling: the role of Tg. J. Pharm. Sci. 2007, 96:1398-1407.
257. Graeser K.A., Strachan C.J., Patterson J.E., Gordon K.C., Rades T. Physicochemical properties and stability of two differently prepared amorphous forms of simvastatin. Cryst. Growth Des. 2008, 8:128-135.
258. Gift A.D., Luner P.E., Luedeman L., Taylor L.S. Influence of polymeric excipients on crystal hydrate formation kinetics in aqueous slurries. J. Pharm. Sci. 2008, 97:5198-5211.
259. Kogermann K., Zeitler J.A., Rantanen J., Rades T., Taday P.F., Pepper M., Heinämäki J., Strachan C.J. Investigating dehydration from compacts using Terahertz pulsed, Raman, and near-infrared spectroscopy. Appl. Spectrosc. 2007, 61:1265-1274.
260. Airaksinen S., Karjalainen M., Räsänen E., Rantanen J., Yliruusi J. Comparison of the effects of two drying methods on polymorphism of theophylline. Int. J. Pharm. 2004, 276:129-141.
261. Stanton M.K., Bak A. Physicochemical properties of pharmaceutical co-crystals: a case study of ten AMG 517 co-crystals. Cryst. Growth Des. 2008, 8:3856-3862.
262. Aitipamula S., Chow P.S., Tan R.B.H. Polymorphs and solvates of a cocrystal involving an analgesic drug, ethenzamide, and 3,5-dinitrobenzoic acid. Cryst. Growth Des. 2010, 10:2229-2238.
263. Aitipamula S., Chow P.S., Tan R.B.H. Dimorphs of a 1:1 cocrystal of ethenzamide and saccharin: solid-state grinding methods result in metastable polymorph. CrystEngComm 2009, 11:889-895.
264. Aitipamula S., Chow P.S., Tan R.B.H. Trimorphs of a pharmaceutical cocrystal involving two active pharmaceutical ingredients: potential relevance to combination drugs. CrystEngComm 2009, 11:1823-1827.
265. Aitipamula S., Chow P.S., Tan R.B.H. Conformational and enantiotropic polymorphism of a 1:1 cocrystal involving ethenzamide and ethylmalonic acid. CrystEngComm 2010, 12:3691-3697.
266. Childs S.L., Chyall L.J., Dunlap J.T., Smolenskaya V.N., Stahly B.C., Stahly G.P. Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. J. Am. Chem. Soc. 2004, 126:13335-13342.